GU Cancers 2024 | Real-world PSA responses to apalutamide or enzalutamide in mCSPC

Benjamin Lowentritt, MD, Chesapeake Urology Research Associates, Baltimore, MD, comments on findings from a real-world study of patients with metastatic castrate sensitive prostate cancer (mCSPC) treated with apalutamide or enzalutamide in conjunction with androgen deprivation therapy (ADT). By 6 months post-initiation, apalutamide demonstrated a higher percentage of patients achieving the PSA90 (reduction of PSA levels by 90%) response compared to enzalutamide. The median time to PSA90 response is notably shorter for apalutamide, emphasizing its potential for generating a deep and early treatment response. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.